TUS-PHARMA: The 58.607 million shares held by the controlling shareholder are subject to judicial auction, and the company's control will change. TUS-PHARMA announced that on August 6, 2025, the company received the "Execution Ruling" from the Beijing Financial Court delivered by Hunan Sailoxian [Jing 74 Zhi 1019]
The ruling transfers 58.607 million shares of TUS-PHARMA held by Qidi Kefu to the buyer Hunan Sailoxian. After this equity change, Qidi Kefu will no longer hold shares in the company, and its concerted actor, Huaqing Investment, will see its shareholding in the company decrease from 63.1514 million shares to 4.5445 million shares, reducing its total shareholding ratio from 26.37% to 1.90%. Hunan Sailoxian will hold 58.607 million shares of the company, accounting for 24.47% of the total share capital. This equity change still needs to complete the transfer and other legal procedures. This equity change does not trigger a tender offer. After the completion of this equity change, Hunan Sailoxian will hold 24.47% of the company's shares. This equity change will lead to a change in the company's control, significantly impacting the company's equity structure and governance
